HOUSE DOCKET, NO. 3233 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 763
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Marjorie C. Decker
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act relative to assessing the feasibility of in-state drug manufacturing.
_______________
PETITION OF:
NAME: DISTRICT/ADDRESS: DATE ADDED:
Marjorie C. Decker 25th Middlesex 1/16/2025
Patrick Joseph Kearney 4th Plymouth 5/8/2025
Estela A. Reyes 4th Essex 5/28/2025
1 of 1

HOUSE DOCKET, NO. 3233 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 763
By Representative Decker of Cambridge, a petition (accompanied by bill, House, No. 763) of
Marjorie C. Decker for an investigation by a special commission (including members of the
General Court) relative to the feasibility of state-sponsored prescription drug manufacturing or
distribution in the Commonwealth. Elder Affairs.
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Fourth General Court
(2025-2026)
_______________
An Act relative to assessing the feasibility of in-state drug manufacturing.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 SECTION 1. (a) Notwithstanding any special or general law to the contrary, there shall
2 be a special commission to investigate and assess the feasibility of state-sponsored prescription
3 drug manufacturing or distribution in the commonwealth. The special commission shall consist
4 of: the secretary of health and human services or a designee, who shall serve as chair; the
5 commissioner of insurance or a designee; the executive director of the center for health
6 information and analysis or a designee; the executive director of the health policy commission or
7 a designee; the president of the board of registration in pharmacy or a designee; the president of
8 the University of Massachusetts or a designee; and 11 persons selected by the chair, 1 of whom
9 shall be a representative of the Massachusetts Biotechnology Council, Inc., 1 of whom shall be a
10 representative of the Massachusetts Health and Hospital Association, Inc., 1 of whom shall be a
11 representative of the Massachusetts Medical Society, 1 of whom shall be a representative of a
12 patient advocacy organization, 1 of whom shall be a representative of an advocacy organization
1 of 4

13 representing patients with lack of access to pharmaceutical products, including but not limited to,
14 insulin, naloxone, albuterol inhalers and epinephrine, 1 of whom shall be a representative of a
15 representative of the office of pharmaceutical policy and analysis established under the section 3
16 of chapter 342 of the acts of 2024, 1 of whom shall be an individual with expertise in biomedical
17 research, 1 of whom shall be a physician licensed to practice medicine under section 2 of chapter
18 112 of the General Laws with expertise in the treatment of diabetes and related complications, 1
19 of whom shall be a physician licensed under said section 2 of said chapter 112 with expertise in
20 the treatment of substance use disorders and related complications, 1 of whom shall be a
21 physician licensed under said section 2 of said chapter 112 with expertise in the treatment of
22 allergic reactions and related complications and 1 of whom shall be a physician licensed under
23 said section 2 of said chapter 112 with expertise in the treatment of asthma and related
24 complications.
25 (b) The special commission shall study and report on the feasibility of state-sponsored
26 drug manufacturing or distribution in the commonwealth. The special commission shall: (i) study
27 the feasibility of manufacturing commonly used pharmaceutical products and their analogs,
28 including but not limited to insulin, naloxone, albuterol inhalers and epinephrine; (ii) assess the
29 feasibility of providing the drug and drug analogs to low-income residents of the commonwealth
30 at no-cost or at a reduced cost on a means-tested basis; (iii) assess the feasibility of partnerships
31 between the commonwealth and other entities, including but not limited to, public universities
32 and existing drug manufacturers, or partnerships between other appropriate entities and an
33 existing drug manufacturer to leverage existing research and manufacturing capacity; (iv)
34 analyze if establishing a state-sponsored drug manufacturing program of commonly used
35 pharmaceutical products and their analogs, including but not limited, to the drugs listed in clause
2 of 4

36 (i) of subsection (b), would lower prescription drug prices for public and private purchasers and
37 consumers (v) study the example of other states that have initiated state-sponsored drug
38 manufacturing and distribution initiatives; and (vi) issue a report on the commissionâ€™s findings
39 and policy recommendations.
40 (c) In its assessment, the commission shall consider the following factors: (i) the number
41 of low-income residents who currently require the drugs listed in clause (i) of subsection (b); (ii)
42 the ability of the commonwealth, the public university system or other appropriate entity, by
43 themselves or in partnership with existing drug manufacturers, to produce the drugs listed in
44 clause (i) of subsection (b); (iii) any long-term cost savings and revenue generation for the
45 commonwealth; (iv) any long-term cost savings and other benefits to low-income residents of the
46 commonwealth who would receive the drugs listed in clause (i) of subsection (b); (v) any costs to
47 the commonwealth to produce the drugs listed in clause (i) of subsection (b), including additional
48 administrative costs; (vi) state and federal regulatory or legal obstacles, including requirements
49 for licensure, to the production and distribution of the drugs listed in clause (i) of subsection (b)
50 within the commonwealth; (vii) available alternative methods for providing the drugs listed in
51 clause (i) of subsection (b) to low-income residents of the commonwealth at low or no cost; (viii)
52 options for capping copayments for the drugs listed in clause (i) of subsection (b) provided
53 through private insurers; (ix) the potential for state-sponsored manufacturing of the drugs listed
54 in clause (i) of subsection (b) to address drug shortages; (x) the potential for the commonwealth
55 to engage in volume purchasing of the drugs listed in clause (i) of subsection (b) at reduced cost;
56 (xi) the mechanisms by which the commonwealth could establish a program to distribute the
57 drugs listed in clause (i) of subsection (b) to residents of the commonwealth; (xii) opportunities
58 to establish an interstate compact with other New England states to reduce costs; (xiii)
3 of 4

59 opportunities to establish a public entity to manage the manufacturing, purchasing or distribution
60 of the drugs listed in clause (i) of subsection (b); (xiv) opportunities to establish a model facility
61 to affordably manufacture the drugs listed in clause (i) of subsection (b); and (xv) opportunities
62 to procure dedicated funding to support the manufacture and distribution of the drugs listed in
63 clause (i) of subsection (b) to residents of the commonwealth.
64 (d) Not later than September 1, 2026, the commission shall submit its report to the clerks
65 of the senate and house of representatives, the joint committee on health care financing and the
66 joint committee on public health.
4 of 4

[DELETED: :D/A:DAEITDSA Dr2x1y4h5s4x5]
[DELETED: Sbdociats0r1r2p]
[DELETED: 3r4i5r6o7r819o0t1p2a3s4c5(6d7t8i9f0a1b2a3e4a5p]
[DELETED: 6(7c8m9a0(1o2t3t4c5c6c7t8a9f0w1c2o3t4i5t6(7d8t]
[DELETED: 9o0o1t2t3c4(5o6j]